Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Net Income (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Net Income for 14 consecutive years, with -$29.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income rose 27.16% year-over-year to -$29.8 million, compared with a TTM value of -$133.8 million through Dec 2025, down 48.07%, and an annual FY2025 reading of -$3.7 million, down 15995.65% over the prior year.
  • Net Income was -$29.8 million for Q4 2025 at Karyopharm Therapeutics, down from -$25.7 million in the prior quarter.
  • Across five years, Net Income topped out at $38.7 million in Q4 2021 and bottomed at -$57.4 million in Q1 2021.
  • Average Net Income over 5 years is -$32.8 million, with a median of -$36.8 million recorded in 2022.
  • The sharpest move saw Net Income skyrocketed 711.4% in 2021, then plummeted 247.12% in 2025.
  • Year by year, Net Income stood at $38.7 million in 2021, then tumbled by 199.53% to -$38.5 million in 2022, then fell by 9.14% to -$42.1 million in 2023, then grew by 2.77% to -$40.9 million in 2024, then rose by 27.16% to -$29.8 million in 2025.
  • Business Quant data shows Net Income for KPTI at -$29.8 million in Q4 2025, -$25.7 million in Q3 2025, and -$35.0 million in Q2 2025.